- Home
- MSD vs ALEC Comparison
MSD vs ALEC Comparison
Compare MSD & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MSD | ALEC |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.5M | 167.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MSD | ALEC |
|---|---|---|
| Price | $7.32 | $2.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | 50.9K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | N/A | $29.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.91 | $1.09 |
| 52 Week High | $7.94 | $3.40 |
Technical Indicators
Market Signals| Indicator | MSD | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 63.14 |
| Support Level | $7.23 | $1.93 |
| Resistance Level | $7.43 | $2.10 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 73.08 | 80.56 |
Price Performance
Historical ComparisonAbout MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.